Literature DB >> 31308827

Gastric antral vascular ectasia should not be overlooked in erythropoietin resistance: a series of case reports.

Laurynas Rimševičius1, Domantas Galkauskas2, Julius Lavinskas3, Evelina Šestelinska2, Ernesta Mačionienė1, Agnė Laučytė-Cibulskienė1, Skirmantė Rėkutė2, Marius Miglinas1.   

Abstract

BACKGROUND: Gastric antral vascular ectasia (GAVE) is currently recognized as an important cause of upper gastrointestinal (GI) haemorrhage, being responsible for about 4% of non-variceal upper GI haemorrhages and typically presents in middle-aged females. GAVE, also called "watermelon stomach", is diagnosed through esophagogastroduodenoscopy and is characterized by the presence of visible columns of red tortuous enlarged vessels along the longitudinal folds of the antrum. The pathogenesis is still obscure and many hypotheses have been proposed such as mechanical stress, humoral and autoimmune factors. In the last two decades, numerous therapeutic strategies have been proposed, including surgical, endoscopic, and medical choices, yet successful treatment of GAVE continues to be a challenge. Currently, given the rapid response, safety, and efficacy, endoscopic ablative modalities have largely usurped medical treatments as first-line therapy, particularly using argon plasma coagulation. The actual GAVE prevalence in patients with end-stage renal disease (ESRD) is not clear, yet in difficult cases it should be considered as a cause of erythropoietin resistance. CASE
PRESENTATION: We report four clinical cases of GAVE syndrome patients diagnosed with stage 4 to 5 chronic kidney disease. All patients presented with anaemia and GI haemorrhage, the origin of which turned out to be GAVE syndrome.
CONCLUSIONS: GAVE syndrome is a serious condition in ESRD patients, especially in those presenting with treatment-refractory anaemia. Realization of its aetiology and characteristics is essential to suspect, diagnose, and treat gastric ectasia. Only proper diagnosis and well-timed disease treatment can significantly improve a patient's medical condition and future prognosis.

Entities:  

Keywords:  ESRD; GAVE; end-stage renal disease; gastric antral vascular ectasia; hemodialysis; watermelon stomach

Year:  2018        PMID: 31308827      PMCID: PMC6591695          DOI: 10.6001/actamedica.v25i4.3932

Source DB:  PubMed          Journal:  Acta Med Litu        ISSN: 1392-0138


  17 in total

Review 1.  Review article: current therapeutic options for gastric antral vascular ectasia.

Authors:  S Sebastian; C A O'Morain; M J M Buckley
Journal:  Aliment Pharmacol Ther       Date:  2003-07-15       Impact factor: 8.171

2.  Severe hemorrhage from gastric vascular ectasia developed in a patient with AML.

Authors:  Tohru Takahashi; Takuya Miya; Mariko Oki; Nobuaki Sugawara; Mitsuru Yoshimoto; Masayuki Tsujisaki
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 3.  Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment.

Authors:  Christian P Selinger; Yeng S Ang
Journal:  Digestion       Date:  2008-04-04       Impact factor: 3.216

4.  Gastric antral vascular ectasia (watermelon stomach) in patients with ESRD.

Authors:  Ioannis Stefanidis; Vassilios Liakopoulos; Andreas N Kapsoritakis; Iraklis Ioannidis; Theodoros Eleftheriadis; Peter R Mertens; Ron Winograd; Eva Vamvaka; Athanasios K Psychos; Spiros P Potamianos
Journal:  Am J Kidney Dis       Date:  2006-06       Impact factor: 8.860

5.  Clinical comparisons between two subsets of gastric antral vascular ectasia.

Authors:  M Ito; Y Uchida; S Kamano; H Kawabata; M Nishioka
Journal:  Gastrointest Endosc       Date:  2001-06       Impact factor: 9.427

6.  Prevalence and natural history of gastric antral vascular ectasia in patients undergoing orthotopic liver transplantation.

Authors:  Eric M Ward; Massimo Raimondo; Barry G Rosser; Michael B Wallace; Rolland D Dickson
Journal:  J Clin Gastroenterol       Date:  2004 Nov-Dec       Impact factor: 3.062

7.  Watermelon stomach: clinical aspects and treatment with argon plasma coagulation.

Authors:  Dalton M Chaves; Paulo Sakai; Cláudio V Oliveira; Spencer Cheng; Shinichi Ishioka
Journal:  Arq Gastroenterol       Date:  2006 Jul-Sep

8.  Endoscopic treatment outcomes in watermelon stomach patients with and without portal hypertension.

Authors:  G S Dulai; D M Jensen; T O G Kovacs; I M Gralnek; R Jutabha
Journal:  Endoscopy       Date:  2004-01       Impact factor: 10.093

9.  The clinical and endoscopic spectrum of the watermelon stomach.

Authors:  C J Gostout; T R Viggiano; D A Ahlquist; K K Wang; M V Larson; R Balm
Journal:  J Clin Gastroenterol       Date:  1992-10       Impact factor: 3.062

10.  Gastrointestinal angiodysplasia in chronic renal failure.

Authors:  H Kaaroud; L Ben Fatma; S Beji; K Boubaker; H Hedri; F Ben Hamida; F El Younsi; T Ben Abdallah; H Ben Maiz; A Kheder
Journal:  Saudi J Kidney Dis Transpl       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.